Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EPS (Weighted Average and Diluted) (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.94 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 370.0% year-over-year to -$0.94; the TTM value through Dec 2025 reached -$3.47, down 306.55%, while the annual FY2025 figure was -$3.47, 306.55% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.94 in Q4 2025 per TRDA's latest filing, up from -$1.06 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.55 in Q2 2024 and bottomed at -$1.06 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.31, with a median of -$0.55 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 423.81% in 2024, then plummeted 370.0% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.78 in 2022, then surged by 64.1% to -$0.28 in 2023, then grew by 28.57% to -$0.2 in 2024, then plummeted by 370.0% to -$0.94 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.94 in Q4 2025, -$1.06 in Q3 2025, and -$1.05 in Q2 2025.